This study evaluated and compared the measurement properties of the 13-item FACITFatigue Scale (FACIT-F) and the 9-item Fatigue Severity Scale (FSS) in 118 consecutive Parkinson's disease (PD) patients, using traditional and Rasch measurement methodologies.
Fatigue can be defined as an overwhelming sense of tiredness, lack of energy, and feeling of exhaustion (1) and is a common complaint in a range of medical conditions, including many neurological disorders (1) (2) (3) . In a clinical context, fatigue is considered to be a multidimensional concept with physical, emotional, cognitive, and social aspects. This can pose a challenge to measurement. In Parkinson's disease (PD), fatigue has been reported in 40-65% of patients and although many consider it to be one of their most disabling symptoms, it often remains undetected in clinical practice (4) (5) (6) (7) (8) . Its cause remains unclear. For example, while some reports suggest an association between fatigue and the underlying parkinsonism (5, 9), others do not (10, 11) .
One reason for such mixed results may relate to how fatigue has been assessed. Studies have tended to use fatigue scales from generic health status questionnaires or approaches not validated in PD (4) (5) (6) (7) (8) (10) (11) (12) . Although generic health status questionnaires have been validated broadly, their subscales are brief and often lack sufficient detail for accurately measuring individuals. For example, the Energy subscale of the Nottingham Health Profile (NHP-EN) (13) has been found to be only a coarse measure of fatigue (14) . Other employed instruments have been validated in other patient groups but remain untested in terms of their measurement properties in PD. This is a limitation because traditional psychometric properties are sample dependent. Thus their performance in specific applications is important to consider in the context of accumulated experience with an instrument (15) . There is thus a need for fatigue measures with documented reliability and validity in specific patient populations, such as PD, that also allow for comparisons with other patient groups and healthy control populations (3).
We therefore sought to identify and validate an available fatigue questionnaire for use in PD. It was considered that such an instrument should have been successfully applied with well documented good measurement properties in various populations, and be brief and easy to incorporate into clinical research protocols without inducing substantial respondent burden (16) . Availability of the instrument in several languages was also desired. Based on these criteria and a review of the literature, we undertook a validation of the 13-item Functional Assessment of Chronic Illness Therapy -Fatigue Scale (FACIT-F), which is part of the larger FACIT measurement system and currently is available in 46 languages (www.facit.org). The questionnaire was originally developed to assess anemia-associated fatigue (17) , but has since been used and validated also in other patient groups, such as rheumatoid arthritis (RA) and various forms of cancer, as well as in the general United States population (18) (19) (20) . In addition, it has been thoroughly documented regarding its responsiveness and minimally important difference (MID) (19, 21, 22) , and recent work (23) has also begun linking FACIT-F scores to levels of physical impairment and activity limitations, which has potential to further facilitate score interpretation. Furthermore, it can be administered via a range of modes, including interview and touch-screen computer administration, and novel modes such as computer-assisted telephone and web-based administration are under development (24) .
Although it did not meet the above criteria regarding measurement properties, the Fatigue Severity Scale (FSS) was also considered due its relatively wide usage among people with PD (25) and the apparent lack of documented measurement properties in this disorder.
The FSS was originally developed and tested for use in multiple sclerosis and systemic lupus erythematosus (26) , and has also been evaluated in, e.g., postpoliomyelitis syndrome and chronic hepatitis C (27, 28) . Here we assess the measurement properties of the FACIT-F, and compare it with the FSS, as applied to people with PD.
METHODS

Design
The study was designed as a cross-sectional, multi-center psychometric comparative study.
Patients
One hundred and twenty four consecutive Swedish speaking patients with clinically diagnosed PD from four Swedish movement disorder clinics were invited to participate. Four patients declined participation, one did not have time to participate, and one was found not to meet inclusion criteria, leaving a total of 118 participants (n=30, 26, 30 and 32 from the respective study sites; no significant differences in dropout rates across study sites). Exclusion criteria were ongoing infections, psychiatric drug adverse reactions and clinically significant co-morbidities (including depression and cognitive impairment), as determined by patients' attending neurologist and the study assessor at the time of assessment. Patients participating in other ongoing studies were also excluded. All participating patients signed informed consent. The study was approved by the local research ethics committees. Patient characteristics are provided in Table 1 .
Procedures
Clinical assessments were performed by one experienced assessor (a PD specialized nurse) at each participating center. Before initiating data collection, all raters underwent standardized video based training (29, 30) (33) . All assessments were performed during the "on" phase (i.e., periods of good drug response and no or minimal PD-related disability). Hoehn & Yahr and Schwab & England were also estimated for the "off" phase (i.e., periods of poor drug response and increased PD-related disability) based on patient reported history and medical records. Patients then completed the fatigue questionnaires (see below) and questionnaires tapping sleep quality, daytime sleepiness, depression, anxiety, perceived adjustment to illness, and illness-related distress. Demographic data were collected by patient interview and from their medical records. Patients were also asked to complete a second copy of the FACIT-F at home one week later together with a question on whether their perceived level of fatigue had changed (according to a 5-grade scale, "much better" -"better" -"unchanged" -"worse" -"much worse") since the clinic assessment. Because the FACIT-F was the primary target instrument, and to minimize respondent burden and maximize retest response rates, the FSS was not included in this aspect of the protocol. Data regarding aspects beyond the measurement properties of the FACIT-F and FSS will be reported separately.
Patient-reported fatigue questionnaires
FACIT-F (17) consists of 13 items ( Table 2 ) that are responded to by affirming one of five Likert-type response categories ("not at all" -"a little bit" -"somewhat" -"quite a bit" -"very much"). The instrument yields a summed total score ranging between 0 and 52 (52 = no fatigue).
The FSS (26) consists of 9 items (Table 2 ) and a 7-grade non-defined Likert-type scale anchored by "completely disagree" (=1) and "completely agree" (=7) at the respective ends. A total FSS score is calculated as the mean response across the 9 items, yielding a score range between 1 and 7 (7 = more fatigue).
The NHP-EN (13) was used to identify the presence of fatigue (5, 14) . Patients who affirmed one or more of its three dichotomous ("yes"/"no") items (Table 2) were classified as fatigued.
All questionnaires had previously been translated into Swedish according to established standardized methods (34-36).
Analyses
The FACIT-F and FSS were evaluated regarding data quality, reliability, floor-and ceiling effects, construct validity, precision of scores, unidimensionality, rating scale functionality, and differential item functioning, using traditional and Rasch measurement methodologies (15, 37, 38) .
Data quality, reliability, floor-and ceiling effects. Data quality relates to the usefulness of an instrument, and is considered high when the percentage of missing data is low.
Reliability was assessed by Cronbach's coefficient alpha, a measure of item interrelatedness and an estimate of reliability. The FACIT-F was also assessed for test-retest reliability by means of the intra-class correlation (ICC) coefficient, by comparing first and second administration scores among patients who reported stable fatigue. Reliability coefficients should not be below 0.7 and preferably >0.8 (37, 39) .
Floor-and ceiling effects represent the percentage of respondents obtaining the lowest and highest possible raw scores, respectively. The threshold for acceptable floor-and ceiling effects was set at 15% (40) .
Construct validity and precision of scores. Two aspects of construct validity, convergent and known-groups validity, were assessed. Convergent validity was evaluated by the correlation between scores on the NHP-EN and the FACIT-F and FSS. Strong correlation coefficients (≥0.6-0.7) were hypothesized. In evaluating known-groups validity, significantly (P<0.05) different FACIT-F and FSS scores between patients classified as fatigued and nonfatigued according to the NHP-EN were expected, and was interpreted as support for knowngroups validity.
The precision by which the FACIT-F and FSS distinguished between these groups was explored by comparing the respective t-statistics, 95% confidence interval (95% CI) widths, and effect sizes (difference between means / full sample SD) following score transformation to 0-100 scales (100 = more fatigue). The effect size expresses differences in standard deviation units, where values of 0.2, 0.5 and 0.8 are regarded as small, moderate and large, respectively (41) . Using the respective t-statistics, the FACIT-F and FSS were also compared regarding their relative efficiency by calculating the squared t-statistics ratio using the smallest t-value as the denominator (42).
Unidimensionality. The extent to which items tap a single underlying latent construct, i.e., unidimensionality, is a basic assumption for the use of summed rating scales and was evaluated by two approaches. First, instruments were subjected to principal component exploratory factor analysis (EFA). The number of factors to extract was determined by parallel analysis (43) . For both the FACIT-F and the FSS, 1000 sets of parallel random data were generated, followed by independent parallel EFAs of the empirical and random data matrices. For each consecutive empirical eigenvalue that exceeded the 95 th percentile of the distribution of random data eigenvalues, a factor was retained (43) . To support unidimensionality, the FACIT-F and FSS should render only one such factor each.
Second, the FACIT-F and FSS were subjected to analyses according to the Rasch rating scale model (38) . According to this model, the probability of a person giving a certain Variables were checked regarding assumptions underlying the use of parametric and non-parametric statistics and described and analyzed accordingly. Analyses were performed using SPSS version 12 (SPSS Inc., Chicago, IL) and WINSTEPS version 3.55 (winsteps.com, Chicago, IL). The alpha-level of significance was set at 0.05. P-values are 2-tailed.
RESULTS
No patients expressed any difficulties understanding or completing the questionnaires.
Descriptive and psychometric statistics of the FACIT-F and FSS are summarized in Table 3 .
Data quality, reliability, floor-and ceiling effects. Both instruments yielded good data quality with few missing item responses (Table 3 ; no significant differences across study sites). Scale scores could be computed for all subjects according to the FACIT-F and for all but 5 patients (4.2%) for the FSS.
Coefficient alpha reliabilities were ≥0.9 (Table 3) , indicating little random measurement error. One-hundred and seven patients (91%) returned the second FACIT-F after an average of 8 days, of whom 87 (81%) reported stable levels of fatigue since they completed the first questionnaire. Test-retest reliability based on scores from stable patients was 0.85 (Table 3) .
Scores from stable patients who responded within 2 weeks (n=81) and during the second week after the initial assessment (n=70) yielded test-retest ICC coefficients of 0.85 and 0.84, respectively.
Floor-and ceiling effects were minimal for both questionnaires (Table 3) , thus supporting their appropriateness for this sample of people with PD.
Construct validity and precision of scores. The FACIT-F correlated strongly with both FSS and NHP-EN scores (Table 4) . FSS scores correlated less strong with NHP-EN scores but the coefficient surpassed the predefined lower bound for support of convergent validity.
The correlation (r) between Rasch calibrated person logit FACIT-F and FSS measures was 0.71, indicating that they measure related but not identical aspects. Both scales were able to correctly discriminate between patients classified as fatigued and non-fatigued (Table 3) 
Differential item functioning (DIF).
Explorative analyses of DIF by gender and age groups did not suggest any signs of DIF in the FACIT-F ( Fig. 2A-B) . Similarly, there were no signs of DIF by gender among FSS items (Fig. 2C) . However, t-tests (but not DIF contrasts) indicated DIF by age for item 1 (DIF contrast = 0.42 logits, t = -2.48, P = 0.015) and item 8
(DIF contrast = 0.44 logits, t = 2.6, P = 0.011) of the FSS (Fig. 2D) . Following Bonferroni correction for multiple comparisons, these differences did not remain significant (P = 0.135 and 0.099, respectively). This provides preliminary support for the validity of comparing and pooling FACIT-F and FSS data across age and gender groups among people with PD.
DISCUSSION
The 13-item FACIT-F and the 9-item FSS are among the most widely used brief fatigue questionnaires in clinical medicine and both have compared favorably to other fatigue instruments in previous evaluations (19, 27, 48, 49) . However, this study appears to be the first head-to-head comparison between the two, and the first documentation of their measurement properties in PD. Both instruments were found to perform well and data provide support for their validity and reliability as self-report fatigue instruments in PD.
Several multidimensional instruments have been developed to address various expressions and/or consequences of fatigue (50, 51). Although such tools play a role in
clinical assessment, they can be hampered by an increase in respondent burden, and it is not clear that conceptual multidimensionality of item content in the realm of fatigue cannot be captured in an assessment that has essentially unidimensional measurement properties. Brief, efficient measurement is particularly useful in clinical trials and other clinical and research applications where patient burden is a concern (16). This aspect becomes particularly salient when considering patient populations that are expected to experience troublesome levels of fatigue.
The study sample represented all five stages of PD according to Hoehn & Yahr, although the overall severity was somewhat skewed towards less severe stages, and enrollment criteria excluded patients with clinically significant co-morbidities, such as depression. This poses some limits to the generalizability of results and may underestimate the occurrence of fatigue in PD. However, the primary purpose of the study was not to provide a representative picture of the prevalence of fatigue in PD, but to assess the measurement properties of the FACIT-F and compare it to those of the FSS. Nevertheless, the magnitude and frequency of fatigue found in this sample were very similar to those previously reported in PD (4, 5, 7). Some differences in age and indices of PD severity were observed across study centers, probably reflecting somewhat different clinic profiles. However, and more importantly, there were no differences regarding fatigue questionnaire response rates, fatigue scores or rates of people classified as fatigued across study sites.
Data quality was high for both instruments, which, together with the lack of reported difficulties and ambiguities, indicates adequate patient perceived acceptability of the questionnaires (15) . Both instruments also demonstrated excellent reliability with coefficient alpha values ≥0.9, indicating that scores can be considered sufficiently reliable to be used at an individual patient level (37, 40) . Evaluations of test-retest reliability of the FACIT-F yielded results compliant with a sufficiently high level of reproducibility to support its feasibility for use in clinical research (37, 39) . These properties are important because insufficient reliability does not only compromise interpretability of scores, but also adversely affects, e.g., their correlations with other measures and sample size requirements in clinical trials (39) .
Floor and ceiling effects were small for both FACIT-F and FSS scores. This is an important aspect of effective outcome assessment because large floor and ceiling effects may compromise responsiveness, i.e., the ability of an instrument to detect change. Due to its cross-sectional design, responsiveness could not be addressed in the present study. The responsiveness of the FACIT-F has, however, been thoroughly evaluated among, e.g., people
with anemia and RA, where it has shown an MID of 3-4 raw score points, corresponding to about 1 standard error of measurement (SEM) and a moderate effect size (19, 21, 22) .
Interestingly, these experiences are in close resemblance with observations reported here. The SEM (= SD x √1-alpha) associated with FACIT-F in this study was thus 3.13, which could indicate that a similar MID (i.e., 3-4 raw score points) may apply also to PD (52). While prospective evidence still is lacking for PD, availability of this type of consistent information facilitates the interpretation and clinical meaning of scores and aids in designing clinical trials. In contrast, evidence regarding the responsiveness of the FSS appears to be lacking (50, 51) . Thus, the FSS has often (53-55), but not always (56) , failed to detect change where other parallel fatigue measures have succeeded. While it is recognized that the observations reported here regarding known-groups differences in fatigue scores cannot be interpreted in terms of responsiveness, the narrower 95% CI of the difference score and larger ES of the FACIT-F, as compared to the FSS, are nevertheless in accordance with the experiences reviewed above. Furthermore, the relative efficiency of 1.55 in favor of the FACIT-F suggests that this instrument would be about 50% more efficient in detecting differences in clinical PD trial fatigue outcomes as compared to the FSS.
A priori expectations regarding convergent and known-groups validity of both the FACIT-F and the FSS were met, thus providing support for the construct validity of the questionnaires. Whereas the FACIT-F correlated relatively strongly with both the FSS and the NHP-EN, the FSS correlated weaker (albeit still within the predefined acceptable range) with the NHP-EN. This is probably due to the somewhat different emphasis of the questionnaires, illustrated also by the correlation between the Rasch derived FACIT-F and FSS person logit measures (where about 50% the variance in one could be explained by that in the other).
While the NHP-EN focuses on feelings of reduced energy, FSS items emphasize functional impact of fatigue (50) . The FACIT-F, on the other hand, appears to cover both aspects.
This may also have contributed to the somewhat stronger EFA-derived second factor of the FACIT-F, as compared to the FSS. Item fit to the Rasch model, on the other hand, indicated one misfitting item in each questionnaire, of which the degree of misfit was greater for the FSS item. However, taken together, and until more data are available, we do not consider these observations to call for any questionnaire revisions, but both appear to define reasonably unidimensional underlying and partly overlapping concepts.
From a substantive point of view, the observed item misfits may, however, suggest that needing to sleep during the day (item An8, FACIT-F) and fatigue-related lack of motivation (item 1, FSS) do not adhere as much as the other items in the respective scales to the same underlying predominant concept. The misfitting FACIT-F item may suggest that fatigue (as defined by the remaining items) differs from daytime sleepiness, a notion that has been suggested elsewhere (25) . While motivational processes have been suggested as an important aspect of fatigue in PD and other brain disorders (2), the observed misfit of the motivation item of the FSS could be due to the functional emphasis of this questionnaire. Thus, while the item may be relevant to fatigue, it may not behave in harmony with the content of the other FSS items. Furthermore, although perceived lack of motivation may not be caused by fatigue (as implied by FSS item 1), central motivational processes may still be an important contributor to the experience of fatigue (2).
Rating scale functionality is a prerequisite for valid interpretation of resulting scores and refers to its shared meaning among respondents (45) . If the rating scale does not function the way it is assumed to among the people using it (due to, e.g., ambiguous distinction between categories), responses may become arbitrary and the resulting scores dubious. In this study, rating scale functioning was acceptable for both the FACIT-F and the FSS. However, while is therefore possible that there is a lack of age and gender DIF also in cancer and general population samples, although the associated misfits argue against this. Furthermore, the sample size of this study was considerably smaller than that by Lai et al. (57), who analyzed responses from about 1000 people in each sample, which increases measurement precision.
Nevertheless, while the DIF results reported here should be viewed as tentative, they support the lack of DIF and hence the validity of pooling and comparing data across genders and age groups in PD for both the FACIT-F and probably also the FSS. However, they also illustrate the need for further DIF evaluations in larger samples, not only across gender and age groups, but also across diagnostic and language-/culture groups.
Recently, Brown and coworkers (58) proposed a PD-specific fatigue questionnaire, the 16-item Parkinson Fatigue Scale. While such condition-and symptom-specific tools can be of value, they may also carry limitations. For example, in contrast to using cross-validated generic instruments, results do not allow for direct comparisons across patient groups or with healthy control populations. This is potentially problematic because of the largely unknown cause(s) of fatigue and the need to identify effective therapy, which both well may be nondisease specific (2, 3) . However, the relative merit of the Parkinson Fatigue Scale and more generic tools such as the FACIT-F and FSS will need to be assessed empirically.
The current study illustrates the need for additional work to fully assess the relative merits and limitations of the FACIT-F and FSS. First, regretfully the FSS was not analyzed regarding test-retest reliability, which therefore needs to be assessed in future studies.
Furthermore, there is a clear need for longitudinal data in order to empirically assess responsiveness and elucidate whether circumstantial indications favoring the FACIT-F in this regard also are supported empirically. It is also possible that the FACIT-F performed better than the FSS due to differences in translation into Swedish. Testing in other languages would be enlightening. The lack of information regarding the responsiveness and MID of the FSS will also need to be addressed in order to establish its relative merits in relation to other fatigue questionnaires, such as the FACIT-F. Finally, more and larger samples are needed to diagnostic group in order to allow for assessment of DIF by culture and diagnosis.
In conclusion, this study provides support for the reliability and validity of two widely used brief generic fatigue questionnaires, the FACIT-F and FSS, as applied among people with PD. When comparing the two, the FACIT-F exhibits better measurement precision and modest but consistent psychometric advantages over the FSS. These observations offer a starting point for evidence-based measurement of fatigue in PD. Availability of psychometrically sound fatigue measures that are applicable and valid across disorders provides a sound basis for advancing our understanding of this common, distressing and under-recognized symptom. b Score range, 1-7 (7 = more fatigue). c No significant differences in FACIT-F or FSS scores, or in proportions of patients classified as fatigued and non-fatigued, across the four study sites. d Should be <0.7 and preferably >0.8 (37, 39) . e Second administration. f One-way random intra-class correlation coefficient for single measures. g Should be <15% (40) . h Median (IQR) / mean (SD) FACIT-F and FSS scores compared between fatigued and nonfatigued patients (as defined by the NHP-EN, see Methods). Levene's test revealed lack of homoscedasticity (i.e., non-equal variances) between FSS scores but not between FACIT-F scores. i P<0.0001 (Mann-Whitney U-and unpaired t-tests), as compared to patients classified as non-fatigued.
FACIT-F, Functional Assessment of Chronic Illness Therapy -Fatigue Scale; FSS, Fatigue Severity Scale; SD, standard deviation; IQR, interquartile range; ICC, intra-class correlation. 
